Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Moonpig delivers mixed update, but unveils new £60m buyback

(Sharecast News) - Greeting cards and gifts retailer Moonpig delivered a mixed fourth-quarter update on Thursday, with full-year revenues slightly missing expectations but margins at the top end of guidance, as it unveiled plans for a new share buyback. Ahead of the close of its financial year, which ends on 30 April, the company said annual revenues would be between £350m and £353m, up from £341.1m the year before but slightly short of the current consensus forecast of £354m.

However, adjusted EBITDA margins should be at the top of the 25-27% guidance range, with double-digit percentage growth expected in adjusted earnings per share.

The company, which operates in the UK and the Netherlands, said it saw a softer start to the second half at the Greetz division, which offers gifts like flowers, chocolate, balloons and beverages alongside the main card offering, though recent trading has improved.

Given strong free cash flow generation, the board has decided to launch a new £60m share buyback which will commence in the next financial year.

Commenting on Thursday's update, analyst David Hughes from broker Shore Capital said Moonpig continues to be a "highly cash-generative business", with high profit margins, low capex requirements and negative working capital.

"With the elevated debt levels following the Buyagift acquisition now well under control [...] this cash generation translates into a step up in the share buyback programme," Hughes said.

"Key for the business going forward will be delivering on sales in the Greetz and Buyagift divisions alongside core Moonpig brand, and with this we see the potential for a return to high-single digit growth alongside these enviable margins."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.